title: Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect.
abstract: Oral tolerance is a recognized procedure for induction of antigen-specific peripheral immune hyporesponsiveness. Recently, it has been shown that oral tolerance can be used to prevent experimental colitis. The aim of this study was to test whether induction of oral tolerance toward proteins extracted from inflammatory and noninflammatory colons can alleviate preexisting experimental colitis. Colitis was induced in BALB/c mice by intracolonic instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS). Mice received five oral doses of colonic proteins extracted from TNBS-induced colitis or normal colons, before, or 7 days after colitis was induced. Standard clinical, macroscopic, and microscopic scores were used for colitis assessment. Serum interferon gamma (IFNgamma) and interleukin (IL)4 levels were measured by enzyme-linked immunosorbent assay. Feeding of colitis- or normal colon-extracted proteins before, or following colitis induction, ameliorated colonic inflammation as shown by decreased diarrhea, increased body weight, reduction of colonic ulcerations, intestinal and peritoneal adhesions, wall thickness, and edema. Histological parameters for colitis were markedly improved in tolerized animals, and there was a significant reduction in inflammatory response and mucosal ulcerations. Tolerized mice developed an increase in IL4 and a decrease in IFNgamma serum levels. The results show that induction of oral tolerance to colitis- or normal colon-extracted proteins down-regulated preexisting anticolon immune response, thereby ameliorating experimental colitis. Tolerance induction was mediated via a shift from a proinflammatory T helper (Th)1 to an anti-inflammatory Th2 immune response.
authors.affiliation: Liver Unit Department of Medicine, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: I
authors.initials: I
authors.lastname: Gotsman
authors.forename: A
authors.initials: A
authors.lastname: Shlomai
authors.forename: R
authors.initials: R
authors.lastname: Alper
authors.forename: E
authors.initials: E
authors.lastname: Rabbani
authors.forename: D
authors.initials: D
authors.lastname: Engelhardt
authors.forename: Y
authors.initials: Y
authors.lastname: Ilan
mesh_terms: D000818:Animals; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D003106:Colon / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D004195:Disease Models, Animal; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology*; D007371:Interferon-gamma / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011506:Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000302:isolation & purification; D012720:Severity of Illness Index; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D014302:Trinitrobenzenesulfonic Acid
chemical_list: D011506:Proteins; D015847:Interleukin-4; D007371:Interferon-gamma; D014302:Trinitrobenzenesulfonic Acid